

Marcello Moccia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8432314/marcello-moccia-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

165
papers

3,173
citations

33
h-index

47
g-index

183
ext. papers

3,985
ext. citations

4.4
avg. IF

5.35
L-index

#	Paper	IF	Citations
165	Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience.. <i>Journal of Clinical Psychology in Medical Settings</i> , 2022 , 1	2	1
164	Association Between Institutional Affiliations of Academic Editors and Authors in Medical Journals.. <i>Journal of General Internal Medicine</i> , 2022 ,	4	
163	Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy).. <i>Multiple Sclerosis Journal</i> , 2022 , 28, 597-607	5	2
162	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 63, 103814	4	0
161	Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series. <i>Journal of the Neurological Sciences</i> , 2022 , 120306	3.2	
160	Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 57, 103431	4	1
159	COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. <i>European Journal of Neurology</i> , 2021 , 28, 3375-3383	6	33
158	Public Engagement and Neurology: An Update. <i>Brain Sciences</i> , 2021 , 11,	3.4	1
157	Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	6
156	Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	10
155	A Retrospective Exploratory Analysis on Cardiovascular Risk and Cognitive Dysfunction in Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
154	Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 925-936	4.1	6
153	Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102802	4	9
152	A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i> , 2021 , 424, 117430	3.2	
151	Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
150	Monocular Diplopia in Idiopathic Intracranial Hypertension: A Case Report and Literature Review. <i>European Journal of Case Reports in Internal Medicine</i> , 2021 , 8, 002509	1.2	
149	Disability assessment using Google Maps. <i>Neurological Sciences</i> , 2021 , 1	3.5	5

148	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 28-38	5	8
147	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021 , 28, 1299-1307	6	1
146	Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 176-177	5	4
145	The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis. <i>European Journal of Neurology</i> , 2021 , 28, 893-900	6	11
144	Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. <i>Neurological Sciences</i> , 2021 , 42, 9-13	3.5	26
143	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1738-1744	5.3	36
142	Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1237-1246	4.1	2
141	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 ,	5.5	13
140	Demyelinating disorders following COVID-19 vaccination. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211046903		
139	Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data. <i>PLoS ONE</i> , 2021 , 16, e0258017	3.7	0
138	Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015-2017 Prevalence. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	5
137	Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 43, 102211	4	1
136	Disability through COVID-19 pandemic: neurorehabilitation cannot wait. <i>European Journal of Neurology</i> , 2020 , 27, e50-e51	6	60
135	Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials. <i>Frontiers in Neurology</i> , 2020 , 11, 489	4.1	7
134	COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 44, 102282	4	9
133	Predictors of Nabiximols (Sativex) discontinuation over long-term follow-up: a real-life study. <i>Journal of Neurology</i> , 2020 , 267, 1737-1743	5.5	6
132	The Use of Social Media and Digital Devices Among Italian Neurologists. <i>Frontiers in Neurology</i> , 2020 , 11, 583	4.1	12
131	Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 542	4.1	14

130	2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis. <i>European Radiology</i> , 2020 , 30, 3813-3822	8	8
129	Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis. <i>NeuroImage: Clinical</i> , 2020 , 26, 102201	5.3	3
128	Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020 , 41, 2249-2253	3.5	
127	Assessing disability and relapses in multiple sclerosis on tele-neurology. <i>Neurological Sciences</i> , 2020 , 41, 1369-1371	3.5	43
126	Generalised boundary shift integral for longitudinal assessment of spinal cord atrophy. <i>NeuroImage</i> , 2020 , 209, 116489	7.9	10
125	The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101514	4	6
124	Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101871	4	12
123	Spinal cord atrophy in a primary progressive multiple sclerosis trial: Improved sample size using GBSI. <i>NeuroImage: Clinical</i> , 2020 , 28, 102418	5.3	6
122	Telemedicine in Parkinson Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. <i>Telemedicine Journal and E-Health</i> , 2020 , 26, 1533-1536	5.9	30
121	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102394	4	1
120	Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 45, 102452	4	26
119	Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. <i>Neurology</i> , 2020 , 95, e2966-e2976		
118	Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). <i>BMC Health Services Research</i> , 2020 , 20, 797	2.9	9
117	Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
116	Fatigue in multiple sclerosis: The role of thalamus. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 6-16	5	26
115	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101461	4	8
114	Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study. <i>Neurological Sciences</i> , 2020 , 41, 2781-2792	3.5	2
113	Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. <i>PLoS ONE</i> , 2019 , 14, e0222012	3.7	9

112	Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon- β and Coenzyme Q10. <i>Brain Sciences</i> , 2019 , 9,	3.4	3
111	Advances in spinal cord imaging in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419840593	6.6	38
110	Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon- β -treated multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286418819074	6.6	33
109	Retinal vascular density in multiple sclerosis: a 1-year follow-up. <i>European Journal of Neurology</i> , 2019 , 26, 198-201	6	16
108	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. <i>Annals of Neurology</i> , 2019 , 86, 704-713	9.4	22
107	Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis. <i>Scientific Reports</i> , 2019 , 9, 18074	4.9	16
106	MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis. <i>Neuroradiology</i> , 2019 , 61, 155-162	3.2	23
105	Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 193-196	4	11
104	Normative values of the Rao@ Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education. <i>Neurological Sciences</i> , 2019 , 40, 713-717	3.5	2
103	Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment. <i>Journal of Neurology</i> , 2019 , 266, 361-368	5.5	6
102	Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 1-6	4	15
101	Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 300-301	5	8
100	Notch3 protein expression in skin fibroblasts from CADASIL patients. <i>Journal of the Neurological Sciences</i> , 2018 , 390, 121-128	3.2	1
99	Why do people search Wikipedia for information on multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 20, 210-214	4	7
98	Cardiovascular profile improvement during Natalizumab treatment. <i>Metabolic Brain Disease</i> , 2018 , 33, 981-986	3.9	4
97	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. <i>Nature Reviews Neurology</i> , 2018 , 14, 75-93	15	84
96	Neurology and the Internet: a review. <i>Neurological Sciences</i> , 2018 , 39, 981-987	3.5	24
95	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018 , 265, 1174-1183	5.5	18

94	Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1706-1714	5	61
93	Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 25, 175-178	4	31
92	A 8-year retrospective cohort study comparing Interferon- β formulations for relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 19, 50-54	4	8
91	Time to reconsider urate: Neuroprotective potential may prevail on cardiovascular risk in animal models and clinical trials. <i>EBioMedicine</i> , 2018 , 37, 5-6	8.8	1
90	e-Health and multiple sclerosis: An update. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1657-1664	5	41
89	Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 13, 28-32	4	11
88	The importance of being persistent to multiple sclerosis treatments. <i>Journal of Clinical Neuroscience</i> , 2017 , 40, 198-199	2.2	
87	CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2017 , 309, 47-50	3.5	16
86	Molecular and Metabolic Imaging in Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2017 , 27, 343-356	3	18
85	A longitudinal real-life comparison study of natalizumab and fingolimod. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 217-222	3.8	16
84	Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis. <i>European Journal of Neurology</i> , 2017 , 24, 446-449	6	1
83	Imaging outcome measures for progressive multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1614-1626	5	42
82	Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015. <i>PLoS ONE</i> , 2017 , 12, e0169489	3.7	12
81	Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. <i>Clinical Immunology</i> , 2017 , 183, 249-253	9	7
80	Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression. <i>European Journal of Neurology</i> , 2017 , 24, 195-204	6	9
79	The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1289-1296	5	27
78	Predictors of the 10-year direct costs for treating multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017 , 135, 522-528	3.8	11
77	Speech discrimination is impaired in parkinsonian patients: Expanding the audiologic findings of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S138-43	3.6	19

76	The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. <i>European Journal of Neurology</i> , 2016 , 23, 1673-1679	6	55
75	Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 90-96	4	15
74	Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2016 , 123, 1399-1402	4.3	19
73	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016 , 39, 405-12.1		58
72	White matter changes and the development of motor phenotypes in de novo Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2016 , 367, 215-9	3.2	19
71	Bilirubin and Uric Acid: Two Different Anti-oxidants in Parkinson's Disease. <i>Cell Biochemistry and Biophysics</i> , 2016 , 74, 91-2	3.2	
70	Teaching Video NeuroImages: Finger clonus: When the pupil surpassed his master. <i>Neurology</i> , 2016 , 86, e118-9	6.5	
69	Can people with multiple sclerosis actually understand what they read in the Internet age?. <i>Journal of Clinical Neuroscience</i> , 2016 , 25, 167-8	2.2	17
68	Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016 , 123, 371-7	4.3	9
67	Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 659-67	5	74
66	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 121	5.3	10
65	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 147	5.3	23
64	Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2016 , 1		2
63	Neuropsychological correlates of Pisa syndrome in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016 , 134, 101-7	3.8	17
62	Google Trends: new evidence for seasonality of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1028-9	5.5	30
61	The Dress: Transforming a web viral event into a scientific survey. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 7, 41-6	4	15
60	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 137-40	3.6	43
59	Gender and non motor fluctuations in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016 , 27, 89-92	3.6	29

58	Impulsive-compulsive behaviors in parkin-associated Parkinson disease. <i>Neurology</i> , 2016 , 87, 1436-1441	6.5	41
57	Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. <i>Neurology</i> , 2016 , 87, 1066	6.5	2
56	Caffeine consumption and the 4-year progression of de novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016 , 32, 116-119	3.6	18
55	Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. <i>Journal of Neurology</i> , 2015 , 262, 961-7	5.5	23
54	Diagnostic challenges of Parkinsonism occurring in multiple sclerosis. <i>Acta Neurologica Belgica</i> , 2015 , 115, 513-5	1.5	
53	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson disease. <i>Movement Disorders</i> , 2015 , 30, 373-8	7	36
52	Uric acid: a potential biomarker of multiple sclerosis and of its disability. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 753-9	5.9	21
51	The Framingham cardiovascular risk score in multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 1176-83	6	39
50	Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> , 2015 , 350, 103-4	3.2	5
49	Season of birth and Parkinson disease: possible relationship?. <i>Neurological Sciences</i> , 2015 , 36, 1457-62	3.5	5
48	Increased bilirubin levels in de novo Parkinson disease. <i>European Journal of Neurology</i> , 2015 , 22, 954-9	6	19
47	How many injections did you miss last month? A simple question to predict interferon beta adherence in multiple sclerosis. <i>Expert Opinion on Drug Delivery</i> , 2015 , 12, 1829-35	8	22
46	Pisa syndrome in Parkinson disease: An observational multicenter Italian study. <i>Neurology</i> , 2015 , 85, 1769-79	6.5	55
45	Mild Cognitive Impairment in newly diagnosed Parkinson disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1219-26	3.6	86
44	Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1215-6	5	6
43	Early cues to detect atypical panthothenate kinase-associated neurodegeneration. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015 , 27, e78-9	2.7	
42	Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson disease. <i>European Journal of Neurology</i> , 2015 , 22, 93-8	6	37
41	Hypomorphic NOTCH3 mutation in an Italian family with CADASIL features. <i>Neurobiology of Aging</i> , 2015 , 36, 547.e5-11	5.6	14

40	Uric acid relates to dopamine transporter availability in Parkinson® disease. <i>Acta Neurologica Scandinavica</i> , 2015 , 131, 127-31	3.8	20
39	Non-Motor Correlates of Smoking Habits in de Novo Parkinson® Disease. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 913-24	5.3	4
38	Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson® disease: a prospective longitudinal study. <i>European Journal of Neurology</i> , 2015 , 22, 253-60	6	48
37	Are granular osmiophilic material deposits an epiphenomenon in CADASIL?. <i>Folia Neuropathologica</i> , 2015 , 53, 168-71	2.6	4
36	Cognitive performances and DAT imaging in early Parkinson® disease with mild cognitive impairment: a preliminary study. <i>Acta Neurologica Scandinavica</i> , 2015 , 131, 275-81	3.8	31
35	Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson® disease patients. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 489-93	3.6	78
34	Quitting smoking: an early non-motor feature of Parkinson® disease?. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 216-20	3.6	15
33	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson® Disease--Report of the JPND Working Group BioLoC-PD. <i>Neuroepidemiology</i> , 2015 , 45, 282-97	5.4	16
32	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson® disease in Italy. <i>Neurological Sciences</i> , 2014 , 35, 379-83	3.5	34
31	Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014 , 27, 276-81	3.8	43
30	Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson® disease. <i>European Journal of Neurology</i> , 2014 , 21, 802-7	6	32
29	Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects. <i>Clinical Otolaryngology</i> , 2014 , 39, 53-7	1.8	7
28	Comment on Szewczyk-Krolikowski et al.: the influence of age and gender on motor and non-motor features of early Parkinson® disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1319-20	3.6	2
27	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson® disease. <i>Journal of Neurology</i> , 2014 , 261, 2112-8	5.5	28
26	Gender differences in non-motor symptoms in early Parkinson® disease: a 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 850-4	3.6	43
25	How does smoking affect olfaction in Parkinson® disease?. <i>Journal of the Neurological Sciences</i> , 2014 , 340, 215-7	3.2	11
24	Is serum uric acid related to non-motor symptoms in de-novo Parkinson® disease patients?. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 772-5	3.6	21
23	JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 807-14	2.9	11

22	Apathy in untreated, de novo patients with Parkinson® disease: validation study of Apathy Evaluation Scale. <i>Journal of Neurology</i> , 2014 , 261, 2319-28	5.5	61
21	Letter by Moccia et al regarding article, "Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss-of-function mechanism". <i>Stroke</i> , 2014 , 45, e128	6.7	3
20	Serpentine tongue in long-term metoclopramide treatment. <i>Neurology Psychiatry and Brain Research</i> , 2014 , 20, 93-95	2.1	2
19	Extreme startle and photomyoclonic response in severe hypocalcaemia. <i>Epileptic Disorders</i> , 2014 , 16, 84-7	1.9	3
18	Progressive parkinsonism, balance difficulties, and supranuclear gaze palsy. <i>JAMA Neurology</i> , 2014 , 71, 104-7	17.2	17
17	Ping-pong gaze: Sherrington would not have done it better. <i>JAMA Neurology</i> , 2014 , 71, 1450	17.2	4
16	Movement disorders as presenting symptoms of AIDS. <i>Basal Ganglia</i> , 2013 , 3, 175-178		1
15	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson® disease. <i>Journal of Neurology</i> , 2013 , 260, 1724-30	5.5	34
14	Serum epidermal growth factor predicts cognitive functions in early, drug-naïve Parkinson® disease patients. <i>Journal of Neurology</i> , 2013 , 260, 438-44	5.5	39
13	Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson® disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". <i>Neurological Sciences</i> , 2013 , 34, 2015-22	3.5	21
12	Reasons driving treatment modification in Parkinson® disease: results from the cross-sectional phase of the REASON study. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 1130-5	3.6	14
11	Gender differences in non-motor symptoms in early, drug naïve Parkinson® disease. <i>Journal of Neurology</i> , 2013 , 260, 2849-55	5.5	61
10	Side of onset does not influence cognition in newly diagnosed untreated Parkinson® disease patients. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 256-9	3.6	23
9	Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson® disease: report of 2 cases. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 483-4	3.6	22
8	Segmental progression of cardinal motor symptoms in Parkinson® disease: a pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013 , 19, 1143-8	3.6	2
7	Non-motor symptoms in early Parkinson® disease: a 2-year follow-up study on previously untreated patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 14-7	5.5	77
6	Abnormal eating behaviors in progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2013 , 20, e47-e48	6	5
5	The heterogeneity of early Parkinson® disease: a cluster analysis on newly diagnosed untreated patients. <i>PLoS ONE</i> , 2013 , 8, e70244	3.7	118

4	Hearing impairment in Parkinson® disease: expanding the nonmotor phenotype. <i>Movement Disorders</i> , 2012 , 27, 1530-5	7	67
3	Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson® disease patients. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 1034-8	3.6	72
2	Malabsorption is uncommon in restless legs syndrome. <i>Movement Disorders</i> , 2011 , 26, 1767-8	7	4
1	Restless legs syndrome is a common feature of adult celiac disease. <i>Movement Disorders</i> , 2010 , 25, 877-81	3.1	34